CIS Oncology

What CIS Oncology does

CIS Oncology is a UK-headquartered (Belfast) healthcare software company that has developed and operated ChemoCare, the UK's leading electronic chemotherapy prescribing and patient management system, since its launch in Leeds in 1996. ChemoCare is used by approximately 80% of NHS chemotherapy centres across England, Scotland, and Wales, with a documented track record of 160+ successful hospital go-lives. The platform is built on a cloud-hosted (HSCN-compliant, via partner Redcentric) SQL architecture with HL7 and SOAP Web services interoperability, integrating with NHS Patient Administration Systems (PAS), Laboratory Information Management Systems (LIMS), Electronic Patient Records (EPR), and the Somerset Cancer Registry. The core platform is extended by four modules: ChemoSchedule for appointment management, ChemoWS for aseptic drug preparation worksheets and labels, ChemoPRO for patient-facing mobile engagement, and ChemoConsent for electronic treatment consent.

The company operates a direct enterprise sales motion targeting NHS Trusts, NHS Foundation Trusts, paediatric oncology centres, and selected private providers such as Beacon Hospital Dublin. Revenue is generated through multi-year subscription contracts covering software licensing, optional hosting, implementation services (delivered using PRINCE2 methodology), bespoke training, and managed reporting/data services. The company holds ISO 13485:2016, ISO 9001:2015, ISO/IEC 27001:2022, Cyber Essentials Plus, and DCB0129 certifications, and ChemoCare v6.05 is MHRA-registered as a Class I medical device. In October 2024 CIS Oncology was acquired by System C, a UK healthcare and local government technology provider, and now operates as a subsidiary focused on extending medicines management capability within System C's EPR, pharmacy, and prescribing portfolio.

Name

CIS Oncology

Legal name

CIS Oncology Ltd

Website

https://cis-healthcare.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

CIS Oncology provides ChemoCare, the UK's leading electronic chemotherapy prescribing and patient management system, used by 80% of NHS centres. The Belfast-based company serves NHS Trusts, paediatric oncology centres, and select private hospitals via a direct enterprise sales model.

Ownership category

akta.pro rank

Product category

Healthcare Clinical Software

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG)

akta.pro secondary industry

Medical Oncology (HLAKAFAB)

Keywords

• Chemotherapy prescribing software
• Patient management systems
• Oncology clinical software
• Electronic prescribing platform
• Healthcare IT systems

Headquarters

HQ city

Belfast

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Software Licencing and Hosting: ChemoCare software licensing with optional HSCN-compliant hosting services through partner Redcentric. Provides cloud-based access with ongoing maintenance, support, and regular upgrades included.
2. Implementation Services: Professional implementation services including project management using PRINCE2 methodology, workflow redesign, clinical input, and specialist governance support.
3. Training Services: Bespoke training programmes including core ChemoCare training, clinical process reviews, train to test/build/schedule sessions for different user roles.
4. Reporting and Data Services: Custom reporting solutions and data extraction services using SQL, SSRS, and Crystal Reports. Bespoke data export systems for research and audit purposes.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels8 records

Core offering

CIS Oncology develops and licenses ChemoCare, the UK's leading electronic chemotherapy prescribing and patient management platform. The system supports adult and paediatric oncology/haematology prescribing, drug preparation documentation, treatment scheduling, and multi-site data sharing. The platform is sold primarily as licensed software with optional HSCN-compliant cloud hosting, bundled with implementation, training, and managed services for NHS Trusts and other healthcare providers.

Product overview

CIS Oncology offers a platform-plus-modules architecture centred on the ChemoCare system, the UK's leading electronic chemotherapy prescribing platform. ChemoCare serves as the core system, while additional modules extend functionality: ChemoSchedule handles appointment scheduling, ChemoWS provides worksheets and labels for drug preparation documentation, ChemoPRO is a patient app for engagement, and ChemoConsent enables electronic patient consent. The company has been providing automated chemotherapy prescribing systems since 1989, with ChemoCare first launched in Leeds in 1996.

Differentiator

Problem solved

Functional benefit

Brands

• ChemoCare: UK's leading electronic chemotherapy prescribing and patient management system, used by hundreds of NHS trusts.
• ChemoSchedule
• ChemoPRO
• ChemoWS

Products and services

• ChemoCare The UK's leading electronic chemotherapy prescribing and patient management platform used by hundreds of NHS trusts. ChemoCare streamlines adult and paediatric oncology/haematology prescribing, drug preparation, treatment scheduling, and multi-site data sharing for cancer treatment centres.
• ChemoSchedule

Quantifiable outcome

• 100% go-live success rate across 160+ UK hospital deployments
• +3 more outcomes

Named customers24 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

Feature8 records

Partnerships

Two partnerships are on record, tiered core.

• System CcoreStrategic or Co-development Partner · 29 October 2024System C acquired CIS Oncology to extend medicines management capability within their healthcare technology portfolio. The acquisition integrates ChemoCare with System C's EPR, maternity, and pharmacy solutions, enabling unified prescribing journeys for clinicians and oncologists.
• RedcentriccoreTechnology or IntegrationCIS Oncology partners with Redcentric for HSCN-compliant cloud hosting of ChemoCare. Redcentric provides 99.95% uptime SLA, self-healing network infrastructure, and Tier 3 data centres in Harrogate and Reading. CIS Oncology retains application and database management.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Elekta: Elekta's MOSAIQ Oncology Information System is a leading radiation/medical oncology OIS used in hospital cancer centres; it competes with ChemoCare in chemotherapy prescribing, scheduling and oncology workflow management within NHS and global oncology departments.
• Varian Medical Systems (Siemens Healthineers): Varian's ARIA oncology information system provides electronic chemotherapy prescribing, treatment management and oncology EHR functionality for cancer centres; it is the most direct global competitor to ChemoCare in chemotherapy e-prescribing.

Broad incumbents

• Oracle Health (formerly Cerner): Oracle Health's Millennium EPR includes oncology and medication management modules used by some NHS Trusts; as a broad incumbent EPR vendor it competes with ChemoCare for chemotherapy prescribing slots during EPR procurements.
• Epic Systems: Epic's Beacon module is an enterprise chemotherapy ordering and management solution embedded within its EPR; while Epic is not UK-focused, it is increasingly deployed in NHS Trusts and competes with ChemoCare at the EPR-chemotherapy boundary.

Emerging players

• Flatiron Health: Flatiron Health (Roche) provides oncology-specific EHR and Real World Evidence platforms for cancer centres and life sciences; it overlaps with CIS Oncology's clinical research and RWE data services use case built on ChemoCare prescribing data.
• RaySearch Laboratories: RaySearch provides oncology information systems (RayCare) for treatment management and workflow in radiation and medical oncology; it competes with ChemoCare in the broader hospital oncology software stack though focused more on radiation oncology.
• Elsevier ClinicalPath (formerly Via Oncology): ClinicalPath provides oncology clinical decision support, treatment pathways and regimen libraries embedded within hospital EHRs; it overlaps with CIS Oncology's protocol decision-tree prescribing approach for chemotherapy regimens.

Others

• System C Healthcare: System C is now the parent company of CIS Oncology and provides EPR, maternity and pharmacy solutions to the NHS; it is a sibling rather than competitor, but its broader portfolio shapes CIS Oncology's competitive context inside multi-vendor NHS procurements.
• IQVIA (Oncology / safety data): IQVIA provides oncology real-world evidence, clinical trial and safety-pharmacovigilance services that consume chemotherapy prescribing data; it is adjacent to CIS Oncology's clinical-research/RWE data services line and a potential partner or competitor for that revenue stream.

Regional players

• MV Health (formerly Jamie / WellSky oncology solutions UK): MV Health and WellSky-style regional oncology workflow and integration providers in the UK compete in adjacent niches (chemotherapy scheduling, pharmacy workflows) that touch ChemoCare's ChemoSchedule and ChemoWS modules within NHS Trust deployments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/cisoncology
• LinkedInlinkedin.com/company/cis-healthcare-limited

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CIS Oncology